Teva Pharmaceuticals Usa, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Teva Pharmaceuticals Usa, Inc Pharmaceutical Import Records from India — 3 Products, $9.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Teva Pharmaceuticals Usa, Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $9.2M Trade | TransData Nexus

Teva Pharmaceuticals Usa, Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $9.2M Total Trade · DGFT Verified

Teva Pharmaceuticals Usa, Inc is a pharmaceutical importer based in United States with a total trade value of $9.2M across 3 products in 2 therapeutic categories. Based on 191 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Teva Pharmaceuticals Usa, Inc sources from 3 verified Indian suppliers, with Piramal Pharma Limited accounting for 65.3% of imports.

Teva Pharmaceuticals Usa, Inc — Import Portfolio & Supplier Network

Teva Pharmaceuticals Usa, Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Teva Pharmaceuticals Usa, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Piramal Pharma Limited	$8.1M	237	65.3%
Watson Pharma Private Limited	$4.1M	104	33.4%
Cipla Limited

What Formulations Does Teva Pharmaceuticals Usa, Inc Import?

Formulation	Value	Ships
(400827004) cilostazol tablets 100MG	$550.8K	12
(400022019) carvedilol tablets 25MG 500s	$463.6K	12
Naproxen sodium extended release	$385.0K	12
(400022016) carvedilol tablets 12.5MG	$375.5K	9
(400827010) cilostazol tablet USP 50MG	$252.8K	6
(400022013) carvedilol tablets 6.25MG	$236.0K	5
(400827011) cilostazol tablet USP 100MG	$200.0K	4
Trientine hydrochloride capsules USP	$200.0K	4
(400824015) doxazosin tabs USP, 4 MG	$199.1K	5
Theophylline extended release tablets	$182.0K	6
(400022010) carvedilol tablets 3.125MG	$166.5K	4
(401132001) flurbiprofen tablets USP	$158.8K	4
(400825001) diltiazem hcl tablets 30MG	$150.0K	3
Tasimelteon capsules 20MG 30's	$150.0K	3
Lanthanum carbonate chewable tablets	$150.0K	3

Teva Pharmaceuticals Usa, Inc imports 197 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Carvedilol	Cardiovascular	$6.8M	136	5.3%	4
2	Diltiazem	Cardiovascular	$1.8M	36	7.5%	2
3	Theophylline	Respiratory	$604.6K	19	2.6%	8

Teva Pharmaceuticals Usa, Inc imports 3 pharmaceutical products across 2 categories into United States totaling $9.2M.

Teva Pharmaceuticals Usa, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Teva Pharmaceuticals USA, Inc. is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of generic and specialty medicines. As a subsidiary of Teva Pharmaceutical Industries Ltd., headquartered in Israel, Teva Pharmaceuticals USA plays a pivotal role in the U.S. healthcare system by providing a broad spectrum of affordable medications. The company offers over 500 generic prescription products across more than 1,500 dosage strengths and forms, including oral solids, injectables, inhaled products, transdermal patches, and topical formulations.

Headquartered in Parsippany, New Jersey, Teva Pharmaceuticals USA operates multiple facilities across the United States, employing nearly 6,100 individuals. The company's extensive distribution network ensures the availability of its products nationwide, serving millions of patients daily. Teva's commitment to innovation is evident in its substantial investment in research and development, aiming to enhance the accessibility and affordability of essential medicines.

2Distribution Network

Teva Pharmaceuticals USA maintains a robust distribution network to ensure the timely delivery of its products across the United States. While specific warehouse locations are not publicly disclosed, the company's operations span multiple states, facilitating efficient logistics and supply chain management. Teva's distribution capabilities are designed to meet the diverse needs of the U.S. healthcare system, ensuring that patients have access to necessary medications without delay.

3Industry Role

In the U.S. pharmaceutical supply chain, Teva Pharmaceuticals USA functions primarily as a wholesaler and distributor. The company sources a wide array of generic and specialty medicines from various manufacturers, including international suppliers, and distributes them to pharmacies, hospitals, and healthcare providers nationwide. This role is crucial in enhancing the accessibility and affordability of medications, thereby improving patient outcomes across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Teva Pharmaceuticals Usa, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Teva Pharmaceuticals USA's sourcing strategy exhibits a significant concentration on a select group of suppliers, particularly from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations totaling $9.2 million from India, encompassing 191 shipments and 197 unique formulations. The top three suppliers during this period were PIRAMAL PHARMA LIMITED, WATSON PHARMA PRIVATE LIMITED, and CIPLA LIMITED, accounting for 65.3%, 33.4%, and 1.3% of the total import value, respectively.

This sourcing pattern indicates a strategic choice to leverage the cost-effectiveness and manufacturing capabilities of these Indian suppliers. The high volume of shipments from PIRAMAL PHARMA LIMITED and WATSON PHARMA PRIVATE LIMITED suggests stable and long-term relationships, which are essential for maintaining a consistent supply of quality products. However, such concentration also presents potential risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within these suppliers.

2Supply Chain Resilience

Teva Pharmaceuticals USA's reliance on a concentrated group of Indian suppliers necessitates a resilient and adaptable supply chain. The company's import data reveals a diverse portfolio of 197 unique formulations, which may help mitigate risks associated with dependency on specific products or suppliers. Nonetheless, the absence of backup suppliers for the top three suppliers indicates a potential vulnerability in the event of supply chain disruptions. To enhance resilience, Teva could consider diversifying its supplier base and establishing contingency plans to ensure uninterrupted access to critical medications.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet the same standards for quality, safety, and effectiveness as domestic products.

For Indian pharmaceutical exporters, obtaining FDA approval is a critical step in entering the U.S. market. This process involves facility registration, drug listing, and compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of foreign manufacturing practices.

2Import Licensing & GMP

To import pharmaceutical products into the United States, foreign manufacturers must register their establishments with the FDA and list all drug products intended for importation. This registration ensures that the manufacturing facilities comply with FDA regulations and are subject to inspections to verify adherence to GMP standards. The FDA accepts GMP certifications from recognized international organizations, such as WHO and PIC/S, which can streamline the approval process for foreign manufacturers.

Teva Pharmaceuticals Usa, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Teva Pharmaceuticals USA's focus on cardiovascular and respiratory medications aligns with the significant demand for these therapeutic areas in the U.S. market. The company's import data indicates that 93.4% of its imports from India are in the cardiovascular category, with carvedilol and diltiazem being the top imported products. The remaining 6.6% pertains to respiratory medications, with theophylline being the primary product. This strategic focus enables Teva to address prevalent health conditions and contribute to improved patient outcomes.

2Sourcing Profile

Teva Pharmaceuticals USA's sourcing strategy emphasizes the procurement of generic drug formulations from India, leveraging the country's manufacturing capabilities and cost advantages. The company's import data reveals a diverse range of 197 unique formulations, indicating a broad sourcing approach within the cardiovascular and respiratory therapeutic categories. This strategy supports Teva's mission to provide a comprehensive portfolio of affordable medications to the U.S. market.

3Market Positioning

Based on its product mix, Teva Pharmaceuticals USA serves multiple segments of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's extensive portfolio of generic medications enables it to meet the needs of various healthcare providers and patients, contributing to the overall efficiency and accessibility of the U.S. healthcare system.

Seller's Guide — How to Become a Supplier to Teva Pharmaceuticals Usa, Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market by meeting Teva Pharmaceuticals USA's sourcing requirements. To capitalize on this opportunity, Indian exporters should focus on ensuring consistent product quality, compliance with FDA regulations, and the ability to meet Teva's supply chain demands. Establishing partnerships with Teva could lead to increased market presence and access to a broad customer base in the U.S. pharmaceutical sector.

2Requirements & Qualifications

Indian exporters aiming to supply Teva Pharmaceuticals USA must obtain FDA approval, which involves facility registration, drug listing, and adherence to GMP standards. The FDA recognizes GMP certifications from international bodies such as WHO and PIC/S, facilitating the acceptance of foreign manufacturing practices. Additionally, exporters must ensure that their products meet FDA labeling requirements, including accurate and informative labeling in English.

3How to Approach

Frequently Asked Questions — Teva Pharmaceuticals Usa, Inc

What products does Teva Pharmaceuticals Usa, Inc import from India?

Teva Pharmaceuticals Usa, Inc imports 3 pharmaceutical products across 2 categories. Top imports: Carvedilol ($6.8M), Diltiazem ($1.8M), Theophylline ($604.6K).

Who supplies pharmaceuticals to Teva Pharmaceuticals Usa, Inc from India?

Teva Pharmaceuticals Usa, Inc sources from 3 verified Indian suppliers. The primary supplier is Piramal Pharma Limited (65.3% of imports, $8.1M).

What is Teva Pharmaceuticals Usa, Inc's total pharmaceutical import value?

Teva Pharmaceuticals Usa, Inc's total pharmaceutical import value from India is $9.2M, based on 191 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Teva Pharmaceuticals Usa, Inc focus on?

Teva Pharmaceuticals Usa, Inc imports across 2 categories. The largest: Cardiovascular (93.4%), Respiratory (6.6%).

Get Full Teva Pharmaceuticals Usa, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.